to study search History No further version available for comparison

Improvement in pain and function through analgesic and anti-inflammatory radiotherapy in patients with finger arthritis, medial/lateral epicondylitis or plantar fasciitis

Organizational Data

DRKS-ID:
DRKS00006288
Recruitment Status:
Recruiting ongoing
Date of registration in DRKS:
2014-07-09
Last update in DRKS:
2014-07-09
Registration type:
Retrospective

Acronym/abbreviation of the study

No Entry

URL of the study

No Entry

Brief summary in lay language

We have successfully treated patients with conditions such as arthitis in our Institute of Radiation Oncology for many years. Radiotherapy can reduce the need for painkillers and other medication, and thus reduce drug-associated side effects (such as bleeding from the stomach and loss of kidney function related to non steroidal anti-inflammatory drugs). The aim of the study is to assess the response to radiotherapy using a questionnaire and clinical tests to document pain and movement. Analysis of the data should lead to an improvement and optimisation of the treatment. Radiotherapy is given twice a week for eight treatments, i.e. over 4 weeks. Each treatment lasts 10 – 15 minutes. The clinical assessments will be performed before the first treatment and 2, 6 and 12 months afer completion of radiotherapy. Furthermore, the patients will be asked to complete a questionnaire at these timepoints. The treatment will be repeated if necessary.

Brief summary in scientific language

In Germany, over 40,000 patients are irradiated for benign conditions each year and account for 10-20% of all radiotherapy patients. Indications include inflammatory soft tissue diseases, degenerative joint diseases and connective tissue diseases such as arthritis, calcaneal spur, tennis elbow and benign vascular tumours. The radiation dose is much lower than in cancer therapy but the success rate is high as recommended by DEGRO (Deutsche Gesellschaft für Radioonkologie . (Ärzte Zeitung Verlags-GmbH, Springer Medizin, 07.12.2011(http://www.aerztezeitung.de/medizin/krankheiten/skelett_und_weichteilkrankheiten/article/682313/strahlentherapie-fersensporn.html)). Radiotherapy can reduce the need for painkillers and other medication, and thus reduce drug-associated side effects (such as gastric haemorrhage and renal impairment secondary to non-steroidal anti-inflammatory drugs ) Strahlentherapie und Onkologie, Rolf Sauer, Verlag: Elsevier, München; Urban & Fischer) The aim of the study is to evaluate pain reduction and gain of function through the analgesic and anti-inflammatory effects of radiotherapy in patients with arthritis of the fingers, medial or lateral epicondylitis or plantar fasciitis. These patients will have been treated with conventional therapeutic interventions for at least 6 months. The efficacy of the radiotherapy will be repeatedly assessed during the first year following completion of therapy. Data will be collected using validated questionnaire and validated clinical tests. There will be no comparison between therapies. Pain will be assessed using the Visual Analog Scale. Musculoskeletal function will be documented using a dynamometer for patients with hand and elbow disorders and a walking test will be performed for patients with plantar fasciitis. The HAQ (health assessment) and EQ-5D (quality of life) questionnaires will be completed by all patients. Assessments will be performed at baseline and at 2, 6 and 12 months after radiotherapy. Treatment will be delivered with 8 x 50 cGy, 2x/week and repeated as necessary.

Health condition or problem studied

Free text:
plantar fasciitis, epicondylitis, polyarthritis of the finger joints
ICD10:
M15.9 - Polyarthrosis, unspecified
ICD10:
M19.9 - Arthrosis, unspecified
ICD10:
M18 - Arthrosis of first carpometacarpal joint
ICD10:
M76 - Enthesopathies of lower limb, excluding foot
ICD10:
M77.0 - Medial epicondylitis
ICD10:
M77.1 - Lateral epicondylitis
ICD10:
M77.3 - Calcaneal spur
ICD10:
M77.5 - Other enthesopathy of foot
ICD10:
M77.9 - Enthesopathy, unspecified
Healthy volunteers:
No Entry

Interventions, Observational Groups

Arm 1:
Analgesic and anti-inflammatory Radiotherapy. Radiotherapy is given twice a week for eight treatments, i.e. over 4 weeks. Each treatment lasts 10 – 15 minutes. The clinical assessments will be performed before the first treatment and 2, 6 and 12 months afer completion of radiotherapy. Furthermore, the patients will be asked to complete a questionnaire at these timepoints. The treatment will be repeated if necessary.

Endpoints

Primary outcome:
Pain will be assessed using the Visual Analog Scale. Musculoskeletal function will be documented using a dynamometer for patients with hand and elbow disorders and a walking test will be performed for patients with plantar fasciitis. The HAQ (health assessment) and EQ-5D (quality of life) questionnaires will be completed by all patients. Assessments will be performed at baseline and at 2, 6 and 12 months after radiotherapy.
Secondary outcome:
none

Study Design

Purpose:
Treatment
Allocation:
N/A (single arm study)
Control:
  • Uncontrolled/single arm
Phase:
N/A
Study type:
Interventional
Mechanism of allocation concealment:
No Entry
Blinding:
No
Assignment:
Single (group)
Sequence generation:
No Entry
Who is blinded:
No Entry

Recruitment

Recruitment Status:
Recruiting ongoing
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Switzerland
Number of study centers:
Monocenter study
Recruitment location(s):
  • Medical center Kantonsspital Aarau Aarau

Recruitment period and number of participants

Planned study start date:
No Entry
Actual study start date:
2013-01-20
Planned study completion date:
No Entry
Actual Study Completion Date:
No Entry
Target Sample Size:
150
Final Sample Size:
No Entry

Inclusion Criteria

Sex:
All
Minimum Age:
40 Years
Maximum Age:
no maximum age
Additional Inclusion Criteria:
Age over 40 year, Karnofsky Index at least 70%, Patients cannot be pregnant, Patients of child bearing age must use a medically acceptable form of contraception during the radiotherapy as well as 12 months after, Patients cannot have any congenital disease with increased sensitivity to radiation, absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial, before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations, patients will have been treated with conventional therapeutic interventions for at least 6 months

Exclusion Criteria

congenital disease with increased sensitivity to radiation, psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

Addresses

Primary Sponsor

Address:
Kantonsspital AarauZentrum für Radio-Onkologie KSA-KSB
5001 Aarau
Switzerland
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry
Investigator Sponsored/Initiated Trial (IST/IIT):
Yes

Contact for Scientific Queries

Address:
Kantonsspital Aarau AGZentrum für Radio-Onkologie KSA-KSB
Dr. med. Brigitte Eberle
Tellstrasse
5001 Aarau
Switzerland
Telephone:
+41628385387
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.ksa.ch

Contact for Public Queries

Address:
Kantonsspital Aarau AGZentrum für Radio-Onkologie KSA-KSB
Susanne Desborough
Tellstrasse
5001 Aarau
Switzerland
Telephone:
+41628385408
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Principal Investigator

Address:
Kantonsspital Aarau AGZentrum für Radio-Onkologie KSA-KSB
Dr. med. Brigitte Eberle
Tellstrasse
5001 Aarau
Switzerland
Telephone:
+41628385387
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.ksa.ch

Sources of Monetary or Material Support

Public funding institutions financed by tax money/Government funding body (German Research Foundation (DFG), Federal Ministry of Education and Research (BMBF), etc.)

Address:
Kantonsspital Aarau AGForschungsrat
5001 Aarau
Switzerland
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Ethics Committee

Address Ethics Committee

Address:
Kanon AargauKantonale Ethikkommssion [Kanton Aargau Kantonale Ethikkommsision Bachstrasse 15 5001 Aarau]
Bachstrasse 15
5001 Aargau
Switzerland
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Vote of leading Ethics Committee

Vote of leading Ethics Committee
Date of ethics committee application:
2012-09-27
Ethics committee number:
2012/069
Vote of the Ethics Committee:
Approved
Date of the vote:
2012-10-25

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
No Entry
UTN (Universal Trial Number):
No Entry
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
No Entry
IPD Sharing Plan:
No Entry

Study protocol and other study documents

Study protocols:
No Entry
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Planned publication:
No Entry
Publikationen/Studienergebnisse:
No Entry
Date of first publication of study results:
No Entry
DRKS entry published for the first time with results:
No Entry

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry